Gain Therapeutics
GANX
28 hedge funds and large institutions have $3.89M invested in Gain Therapeutics in 2024 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 10 increasing their positions, 6 reducing their positions, and 6 closing their positions.
67% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 6
33% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 6
8% more funds holding
Funds holding: 26 → 28 (+2)
2.94% more ownership
Funds ownership: 9.13% → 12.07% (+2.9%)
45% less capital invested
Capital invested by funds: $7.04M → $3.89M (-$3.15M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TIM
Timelo Investment Management
Aurora,
Ontario, Canada
|
+$1.57M |
| 2 |
Alyeska Investment Group
Chicago,
Illinois
|
+$1.17M |
| 3 |
HWM
Hohimer Wealth Management
Seattle,
Washington
|
+$857K |
| 4 |
CCC
Cable Car Capital
San Francisco,
California
|
+$376K |
| 5 |
Renaissance Technologies
New York
|
+$187K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RJA
Raymond James & Associates
St Petersburg,
Florida
|
-$980K |
| 2 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$645K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$162K |
| 4 |
Millennium Management
New York
|
-$54.6K |
| 5 |
Simplex Trading
Chicago,
Illinois
|
-$23.2K |
GANX Hedge Fund Activity: Q2 2024 in Review
28 of the 6,935 institutional investors tracked by Wall St. Rank reported a position in Gain Therapeutics (GANX) for Q2 2024, worth a combined $3.89M — down 45% from $7.04M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new GANX positions and 6 closed out — a net gain of 2 holders — while 10 added to existing stakes and 6 trimmed.
The largest buyer was Timelo Investment Management, opening a new position worth an estimated $1.57M. The largest seller was Raymond James & Associates, exiting entirely with an estimated $980K sold.
- 28 institutional investors held Gain Therapeutics (GANX) as of Q2 2024, up from 26 in Q1 2024.
- Funds reported $3.89M of Gain Therapeutics stock for Q2 2024, down 45% quarter-over-quarter.
- 8 funds opened new Gain Therapeutics positions in Q2 2024 and 6 closed out, a net change of +2 holders.
- The largest Gain Therapeutics buyer in Q2 2024 was Timelo Investment Management, an estimated $1.57M added.
- The largest Gain Therapeutics seller in Q2 2024 was Raymond James & Associates, an estimated $980K sold.
Based on aggregated 13F filings for Q2 2024.